(Q36679594)

15 August 2017

1 reference

title

Cardiovascular disease prevention in patients with type 2 diabetes: The role of oral anti-diabetic agents (English)

1 reference

15 August 2017

1 reference

1 reference

cardiovascular disease

1 reference

Ramzi A Ajjan

1

1 reference

15 August 2017

Peter J Grant

series ordinal

2

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 December 2006

1 reference

Diabetes and Vascular Disease Research

15 August 2017

published in

1 reference

15 August 2017

volume

3

1 reference

15 August 2017

issue

3

1 reference

15 August 2017

page(s)

147-158

1 reference

Lifetime Risk for Diabetes Mellitus in the United States

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes?

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

21 January 2018

The metabolic syndrome

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

Banting lecture 1988. Role of insulin resistance in human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

Role of endothelial dysfunction in atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

Coagulation and atherothrombotic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

Oxidative stress in atherogenesis and arterial thrombosis: the disconnect between cellular studies and clinical outcomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

Inflammation and atherosclerosis: role of C-reactive protein in risk assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

Pathophysiology of insulin resistance in human disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

Insulin sensitivity in subjects with type 2 diabetes. Relationship to cardiovascular risk factors: the Insulin Resistance Atherosclerosis Study

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

Insulin resistance: From predisposing factor to therapeutic target in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23)

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

Dyslipidemia and hyperglycemia predict coronary heart disease events in middle-aged patients with NIDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

Type 2 diabetes, cardiovascular risk, and the link to insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

Lipids and lipoproteins predicting coronary heart disease mortality and morbidity in patients with non-insulin-dependent diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

Long-term risk reduction: who needs treatment?

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

REVIEW: Efficacy and mechanisms of action of statins in the treatment of diabetic dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

Hypertriglyceridemia and the fibrate trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

Diabetes and cardiovascular disease. The Framingham study

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

Overview of hemostatic factors involved in atherosclerotic cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

Blood pressure, stroke, and coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

Predictors of mortality in insulin dependent diabetes: 10 year observational follow up study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

Urinary excretions of high molecular weight beta-thromboglobulin and albumin are independently associated with coronary heart disease in women, a nested case-control study of middle-aged women in the Diagnostisch Onderzoek Mammacarcinoom (DOM) Cohor

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals.

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

Albuminuria reflects widespread vascular damage. The Steno hypothesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue?

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X.

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

Circulating cell adhesion molecules and death in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

Cytokine milieu tends toward inflammation in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

Serum paraoxonase is reduced in type 1 diabetic patients compared to non-diabetic, first degree relatives; influence on the ability of HDL to protect LDL from oxidation

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

Endothelial dysfunction, inflammation and diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

Pathways linking depression, adiposity, and inflammatory markers in healthy young adults

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

Plasma leptin concentration in patients with Type 2 diabetes: relationship to cardiovascular disease risk factors and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

Adiponectin--journey from an adipocyte secretory protein to biomarker of the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

Serum leptin and myocardial infarction in hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

Plasma adiponectin levels and risk of myocardial infarction in men.

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

Insulin resistance as a therapeutic target for improved endothelial function: metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

Metformin monotherapy for type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

Does metformin decrease blood pressure in patients with Type 2 diabetes intensively treated with insulin?

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

Cardiovascular effects of treatment of type 2 diabetes with pioglitazone, metformin and gliclazide

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

The effects of oral anti-hyperglycaemic medications on serum lipid profiles in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

Microalbuminuria as a marker of cardiovascular risk in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

Metformin reduces C-reactive protein but not complement factor C3 in overweight patients with Type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

Metformin delays the manifestation of diabetes and vascular dysfunction in Goto-Kakizaki rats by reduction of mitochondrial oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

Metformin increases circulating tumour necrosis factor-alpha levels in non-obese non-diabetic patients with coronary heart disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

The effects of rosiglitazone and metformin on the plasma concentrations of resistin in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

Metformin improves endothelial function in patients with metabolic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

Sulfonylureas and cardiovascular effects: from experimental data to clinical use. Available data in humans and clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

The impact of ATP-sensitive K+ channel subtype selectivity of insulin secretagogues for the coronary vasculature and the myocardium

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

21 January 2018

Insulin secretagogues

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin-1 and albumin excretion in diabetes patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

Effect of antidiabetic medications on microalbuminuria in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

Adiponectin and C-reactive protein in obesity, type 2 diabetes, and monodrug therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

Plasma adiponectin plays an important role in improving insulin resistance with glimepiride in elderly type 2 diabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

Sulfonylureas and platelet function

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

Antiaggregatory activity of hypoglycaemic sulphonylureas

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

Treating insulin resistance in type 2 diabetes with metformin and thiazolidinediones.

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

Diabetic dyslipidaemia: insights for optimizing patient management

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

Thiazolidinediones and blood lipids in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

Effects of pioglitazone on lipid and lipoprotein profiles in patients with type 2 diabetes and dyslipidaemia after treatment conversion from rosiglitazone while continuing stable statin therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

Cardiovascular effects of the thiazolidinediones.

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

Effects of pioglitazone in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

Rapid effects of rosiglitazone treatment on endothelial function and inflammatory biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

Rosiglitazone reduces urinary albumin excretion in type II diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

The effects of PPAR-gamma ligand pioglitazone on platelet aggregation and arterial thrombus formation

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

Peroxisome proliferator-activated receptor gamma ligands increase release of nitric oxide from endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

PPARgamma and atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces circulating platelet activity in patients without diabetes mellitus who have coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

21 January 2018

Oral Antidiabetic Agents

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

An Asian multicenter clinical trial to assess the efficacy and tolerability of acarbose compared with placebo in type 2 diabetic patients previously treated with diet. Asian Acarbose Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

Improved glycemic control and lipid profile in a randomized study of pioglitazone compared with acarbose in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

Cardiovascular benefits of acarbose in impaired glucose tolerance and type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

Alpha-glucosidase inhibitors for type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

Metformin attenuates progression of carotid arterial wall thickness in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

Pioglitazone reduces neointima volume after coronary stent implantation: a randomized, placebo-controlled, double-blind trial in nondiabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients: a longitudinal study

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

Treatment with rosiglitazone reduces hyperinsulinemia and improves arterial elasticity in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

The effect of gliclazide and glibenclamide on preconditioning of the human myocardium

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

PROactive Study: (r)evolution in the therapy of diabetes?

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

The PROactive study: some answers, many questions

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

Commentary: the PROactive study--the glass is half full

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

Preventing type II diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

The antihyperglycaemic effect of metformin: therapeutic and cellular mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.023

21 January 2018

Identifiers

DOI

10.3132/DVDR.2006.023

1 reference

15 August 2017

1 reference